Rights and permissions
About this article
Cite this article
PEG IFN-α-2b plus ribavirin worth its cost in chronic hepatitis C. Pharmacoecon. Outcomes News 404, 8 (2003). https://doi.org/10.1007/BF03276002
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03276002